Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles

Abstract

Cholangiocarcinoma (CCA) is an aggressive malignancy of the bile ducts, with poor prognosis and limited treatment options. Here, we describe the integrated analysis of somatic mutations, RNA expression, copy number, and DNA methylation by The Cancer Genome Atlas of a set of predominantly intrahepatic CCA cases and propose a molecular classification scheme. We identified an IDH mutant-enriched subtype with distinct molecular features including low expression of chromatin modifiers, elevated expression of mitochondrial genes, and increased mitochondrial DNA copy number. Leveraging the multi-platform data, we observed that ARID1A exhibited DNA hypermethylation and decreased expression in the IDH mutant subtype. More broadly, we found that IDH mutations are associated with an expanded histological spectrum of liver tumors with molecular features that stratify with CCA. Our studies reveal insights into the molecular pathogenesis and heterogeneity of cholangiocarcinoma and provide classification information of potential therapeutic significance.

References 55

1. 1.

   Andersen JB, Spee B, Blechacz BR, Avital I, Komuta M, Barbour A, Conner EA, Gillen MC, Roskams T, Roberts LR, et al. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology. 2012;142:1021-1031.

   Not in our library10.1053/j.gastro.2011.12.005

2. 2.

   Arai Y, Totoki Y, Hosoda F, Shirota T, Hama N, Nakamura H, Ojima H, Furuta K, Shimada K, Okusaka T, et al. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology. 2014;59:1427-1434.

   Not in our library10.1002/hep.26890

3. 3.

   Bledsoe JR, Shinagare SA, Deshpande V. Difficult diagnostic problems in pancreatobiliary neoplasia. Arch Pathol Lab Med. 2015;139:848-857.

   Not in our library10.5858/arpa.2014-0205-ra

4. 4.
   Integrated Genomic Characterization Reveals Novel, Therapeutically Relevant Drug Targets in FGFR and EGFR Pathways in Sporadic Intrahepatic Cholangiocarcinoma · 2014

   No notice
5. 5.

   Borger DR, Tanabe KK, Fan KC, Lopez HU, Fantin VR, Straley KS, Schenkein DP, Hezel AF, Ancukiewicz M, Liebman HM, et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist. 2012;17:72-79.

   Not in our library10.1634/theoncologist.2011-0386

6. 6.

   Brat DJ, Verhaak RG, Aldape KD, Yung WK, Salama SR, Cooper LA, Rheinbay E, Miller CR, Vitucci M, Morozova O, et al. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med. 2015;372:2481-2498.

   Not in our library10.1056/nejmoa1402121

7. 7.

   Burris H, Mellinghoff I, Maher E, Wen P, Beeram M, Touat M, Faris J, Azad N, Cloughesy T, Gore L, et al. Abstract PL04-05: The first reported results of AG-120, a first-in-class, potent inhibitor of the IDH1 mutant protein, in a Phase I study of patients with advanced IDH1-mutant solid tumors, including gliomas. Mol Cancer Ther. 2015;14:PL04-PL05.

   Not in our library

8. 8.

   Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368:2059-2074.

   Not in our library10.1056/nejmoa1301689

9. 9.

   Chan-On W, Nairismägi ML, Ong CK, Lim WK, Dima S, Pairojkul C, Lim KH, McPherson JR, Cutcutache I, Heng HL, et al. Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat Genet. 2013;45:1474-1478.

   Not in our library10.1038/ng.2806

10. 10.
    Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications · 2014

    No notice
11. 11.

    Covington K, Shinbrot E, Wheeler DA. Mutation signatures reveal biological processes in human cancer. bioRxiv. 2016.

    Not in our library

12. 12.

    Cuyàs E, Fernández-Arroyo S, Corominas-Faja B, Rodríguez-Gallego E, Bosch-Barrera J, Martin-Castillo B, Llorens RD, Joven J, Menendez JA. Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype. 2015;6:12279-12296.

    Not in our library10.18632/oncotarget.3733

13. 13.

    Davis CF, Ricketts CJ, Wang M, Yang L, Cherniack AD, Shen H, Buhay C, Kang H, Kim SC, Fahey CC, et al. The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell. 2014;26:319-330.

    Not in our library10.1016/j.ccr.2014.07.014

14. 14.

    Fan B, Malato Y, Calvisi DF, Naqvi S, Razumilava N, Ribback S, Gores GJ, Dombrowski F, Evert M, Chen X, Willenbring H. Cholangiocarcinomas can originate from hepatocytes in mice. J Clin Invest. 2012;122:2911-2915.

    Not in our library10.1172/jci63212

15. 15.

    Fu X, Chin RM, Vergnes L, Hwang H, Deng G, Xing Y, Pai MY, Li S, Ta L, Fazlollahi F, et al. 2-hydroxyglutarate inhibits ATP synthase and mTOR signaling. Cell Metab. 2015;22:508-515.

    Not in our library10.1016/j.cmet.2015.06.009

16. 16.

    Goyal L, Saha SK, Liu LY, Siravegna G, Leshchiner I, Ahronian LG, Lennerz JK, Vu P, Deshpande V, Kambadakone A, et al. Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma. Cancer Discov. 2016.

    Not in our library10.1158/2159-8290.cd-16-1000

17. 17.

    Grassian AR, Parker SJ, Davidson SM, Divakaruni AS, Green CR, Zhang X, Slocum KL, Pu M, Lin F, Vickers C, et al. IDH1 mutations alter citric acid cycle metabolism and increase dependence on oxidative mitochondrial metabolism. Cancer Res. 2014;74:3317-3331.

    Not in our library10.1158/0008-5472.can-14-0772-t

18. 18.

    Hoadley KA, Yau C, Wolf DM, Cherniack AD, Tamborero D, Ng S, Leiserson MD, Niu B, McLellan MD, Uzunangelov V, et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell. 2014;158:929-944.

    Not in our library10.1016/j.cell.2014.06.049

19. 19.

    Holczbauer A, Factor VM, Andersen JB, Marquardt JU, Kleiner DE, Raggi C, Kitade M, Seo D, Akita H, Durkin ME, Thorgeirsson SS. Modeling pathogenesis of primary liver cancer in lineage-specific mouse cell types. Gastroenterology. 2013;145:221-231.

    Not in our library10.1053/j.gastro.2013.03.013

20. 20.

    Jiao Y, Pawlik TM, Anders RA, Selaru FM, Streppel MM, Lucas DJ, Niknafs N, Guthrie VB, Maitra A, Argani P, et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet. 2013;45:1470-1473.

    Not in our library10.1038/ng.2813

21. 21.

    Kelley RK, Bardeesy N. Biliary tract cancers: Finding better ways to lump and split. J Clin Oncol. 2015;33:2588-2590.

    Not in our library10.1200/jco.2015.61.6953

22. 22.

    Kim KH, Kim W, Howard TP, Vazquez F, Tsherniak A, Wu JN, Wang W, Haswell JR, Walensky LD, Hahn WC, et al. SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2. Nat Med. 2015;21:1491-1496.

    Not in our library10.1038/nm.3968

23. 23.

    Kipp BR, Voss JS, Kerr SE, Barr Fritcher EG, Graham RP, Zhang L, Highsmith WE, Zhang J, Roberts LR, Gores GJ, Halling KC. Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. Hum Pathol. 2012;43:1552-1558.

    Not in our library10.1016/j.humpath.2011.12.007

24. 24.

    LaFave LM, Béguelin W, Koche R, Teater M, Spitzer B, Chramiec A, Papalexi E, Keller MD, Hricik T, Konstantinoff K, et al. Loss of BAP1 function leads to EZH2-dependent transformation. Nat Med. 2015;21:1344-1349.

    Not in our library10.1038/nm.3947

25. 25.

    Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH, Roberts SA, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499:214-218.

    Not in our library10.1038/nature12213

26. 26.

    Leonardi R, Subramanian C, Jackowski S, Rock CO. Cancer-associated isocitrate dehydrogenase mutations inactivate NADPH-dependent reductive carboxylation. J Biol Chem. 2012;287:14615-14620.

    Not in our library10.1074/jbc.c112.353946

27. 27.

    Liau JY, Tsai JH, Yuan RH, Chang CN, Lee HJ, Jeng YM. Morphological subclassification of intrahepatic cholangiocarcinoma: Etiological, clinicopathological, and molecular features. Modern Pathol. 2014;27:1163-1173.

    Not in our library10.1038/modpathol.2013.241

28. 28.

    Lonsdale J, Thomas J, Salvatore M, Phillips R, Lo E, Shad S, Hasz R, Walters G, Garcia F, Young N, et al. The Genotype-Tissue Expression (GTEx) project. Nat Genet. 2013;45:580-585.

    Not in our library10.1038/ng.2653

29. 29.

    Losman JA, Kaelin WG. What a difference a hydroxyl makes: Mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev. 2013;27:836-852.

    Not in our library10.1101/gad.217406.113

30. 30.

    Marquardt JU, Andersen JB, Thorgeirsson SS. Functional and genetic deconstruction of the cellular origin in liver cancer. Nat Rev Cancer. 2015;15:653-667.

    Not in our library10.1038/nrc4017

31. 31.

    Martinez-Pastor B, Cosentino C, Mostoslavsky R. A tale of metabolites: The cross-talk between chromatin and energy metabolism. Cancer Discov. 2013;3:497-501.

    Not in our library10.1158/2159-8290.cd-13-0059

32. 32.

    Meng Z, Fu X, Chen X, Zeng S, Tian Y, Jove R, Xu R, Huang W. miR-194 is a marker of hepatic epithelial cells and suppresses metastasis of liver cancer cells in mice. Hepatology. 2010;52:2148-2157.

    Not in our library10.1002/hep.23915

33. 33.

    Nakamura H, Arai Y, Totoki Y, Shirota T, Elzawahry A, Kato M, Hama N, Hosoda F, Urushidate T, Ohashi S, et al. Genomic spectra of biliary tract cancer. Nat Genet. 2015;47:1003-1010.

    Not in our library10.1038/ng.3375

34. 34.

    Nakanuma Y, Sato Y, Ikeda H, Harada K, Kobayashi M, Sano K, Uehara T, Yamamoto M, Ariizumi S, Park YN, et al. Intrahepatic cholangiocarcinoma with predominant “ductal plate malformation” pattern: A new subtype. Am J Surg Pathol. 2012;36:1629-1635.

    Not in our library10.1097/pas.0b013e31826e0249

35. 35.

    Oishi N, Kumar MR, Roessler S, Ji J, Forgues M, Budhu A, Zhao X, Andersen JB, Ye QH, Jia HL, et al. Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma. Hepatology. 2012;56:1792-1803.

    Not in our library10.1002/hep.25890

36. 36.

    Ong CK, Subimerb C, Pairojkul C, Wongkham S, Cutcutache I, Yu W, McPherson JR, Allen GE, Ng CC, Wong BH, et al. Exome sequencing of liver fluke-associated cholangiocarcinoma. Nat Genet. 2012;44:690-693.

    Not in our library10.1038/ng.2273

37. 37.

    Palmer WC, Patel T. Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. J Hepatol. 2012;57:69-76.

    Not in our library10.1016/j.jhep.2012.02.022

38. 38.

    Parker SJ, Metallo CM. Metabolic consequences of oncogenic IDH mutations. Pharmacol Ther. 2015;152:54-62.

    Not in our library10.1016/j.pharmthera.2015.05.003

39. 39.

    Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet. 2014;383:2168-2179.

    Not in our library10.1016/s0140-6736(13)61903-0

40. 40.
    Mitochondrial DNA copy number variation across human cancers · 2016

    No notice

Cited by papers we hold 10

• Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses · 2022
  Not checked
• Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development · 2021
  No notice
• Small molecules in targeted cancer therapy: advances, challenges, and future perspectives · 2021
  No notice
• Case Report: BAP1 Mutation and RAD21 Amplification as Predictive Biomarkers to PARP Inhibitor in Metastatic Intrahepatic Cholangiocarcinoma · 2020
  Not checked
• Cholangiocarcinoma 2020: the next horizon in mechanisms and management · 2020
  No notice
• Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types · 2019
  No notice
• Review of applications of high-throughput sequencing in personalized medicine: barriers and facilitators of future progress in research and clinical application · 2019
  No notice
• Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics · 2019
  No notice
• ELF3, ELF5, EHF and SPDEF Transcription Factors in Tissue Homeostasis and Cancer · 2018
  Not checked
• Liver Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells · 2017
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.